Neurogene has faced a challenging period, with its shares down approximately 32% over the past three months, largely due to a broader downturn in biotech stocks and disappointing second-quarter financial results. However, JPMorgan analyst Priyanka Grover believes the company's gene therapy, NGN-401, which targets Rett syndrome, could be a significant growth driver.
The therapy utilizes the EXACT transgene platform to deliver a functional protein and is expected to generate new trial data in 2027, which could serve as a catalyst for the stock's recovery. Notably, all ten analysts covering Neurogene currently hold a buy or strong buy rating, reflecting a consensus optimism about the company's future prospects